Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients

Purpose: This Phase Ib/II study is an open label, multicenter study.

The study is divided in two parts:

Phase I: an open-label, dose escalation study of F16IL2 in combination with paclitaxel for patients with solid tumours, bladder cancer, breast cancer, metastatic melanoma, mesothelioma, NSCLC, prostate cancer and sarcoma amenable to taxane therapy.

Phase II: a prospective, single-arm, multicentre study of a fixed dose of F16IL2 in combination with paclitaxel, equivalent to stage 1 of the Simon two-stage phase II design, for patients with metastatic melanoma, breast cancer and NSCLC amenable to taxane therapy.

Read More

Asbestos exposure is still a worldwide threat

Asbestos seems like a threat long since past. Most countries stopped using it in buildings by the 1990s and many have removed the dangerous substance in the years following. When the mesothelioma commercials flash across the screen, people don’t pay attention to the real threat of asbestos exposure. Residents of Canberra, Australia, deal with the…

Read More

Libby, Montana faces new asbestos-related threats

While exploring northwestern Montana in 1916, prospectors made a unique discovery in the mountains that would forever affect the people in the nearby town of Libby.  This strange mineral was resistant to high heat and fire, making it ideal for construction materials. Mining began three years later of the vermiculite, called Zonolite by the early…

Read More

MPM PDT Phase II Trial

Purpose: A randomized Phase II trial to test whether the addition of intraoperative Photofrin-mediated photodynamic therapy to radical pleurectomy and post-operative chemo.improves OS in the treatment of patients with epithelioid MPM. Subjects assigned to the PDT arm will be given the photosensitizer prior to surgery . All subjects will receive maximal surgical debulking. Subjects in the PDT arm will receive intraoperative treatment using real-time, isotropic light dosimetry.

Read More

CART-meso in Mesothelin Expressing Cancers

Purpose: Phase I study to establish safety and feasibility of intravenously administered lentiviral transduced CART-meso cells administered with and without cyclophosphamide in a 3+3 dose escalation design in patients with metastatic pancreatic cancer, serous epithelial ovarian cancer, or pleural mesothelioma. Dose: 1-3xE7 /mE2 (Cohort 1 and 2) and 1-3xE8 /mE2 (Cohort 3 and 4 ) CAR+ T cells by intravenous route. In the event of 2 DLTs at each dose level, we will dose deescalate by 10-fold.

Read More

Study finds new treatment boosts chemotherapy results in mesothelioma

Researchers with the National Cancer Institute recently found an immunotoxin may increase the efficacy of chemotherapy. When combined with popular treatments cisplatin and pemetrexed, SS1P caused antitumor activity in patients. SS1P is an immunotoxin, a protein made by humans with a large targeting section linked to a toxin. Specifically, SS1P was created to attack an…

Read More

Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer

Purpose: This Phase 1/2 study is designed to assess the following: safety and tolerability of BIW-8962, Dose Limiting Toxicities (DLTs), Maximum Tolerated Dose (MTD), Recommended Phase 2 Dose (RP2D) in Phase 1 in subjects with advanced/recurrent lung cancers or mesothelioma and preliminary efficacy in Phase 2 in subjects with advanced/recurrent Small Cell Lung Cancer.

Read More

New chemical raises rats’ chance of mesothelioma

Mesothelioma is a rare cancer affecting around 3,000 Americans each year. In more than 70 percent of the cases, asbestos exposure is the main cause. A recent two-year study may have determined another leading contributor to the deadly disease. Rats exposed to vinylidene chloride (VDC), an industrial toxicant, had higher malignant mesothelioma rates. The exposure…

Read More

Grapes and leukemia treatment may help mesothelioma

Several research articles recently published detail new and innovative drug solutions to fight mesothelioma. Scientists from around the world continue to develop potential solutions with Korea releasing their findings tied to a leukemia treatment and red wine. Published in Biochemistry and Molecular Biology, the study found clofarabine, a drug typically used with relapsed leukemia cases…

Read More